Literature DB >> 22832786

Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension.

Mark L Ormiston1, Chiwen Chang, Lu L Long, Elaine Soon, Des Jones, Rajiv Machado, Carmen Treacy, Mark R Toshner, Kate Campbell, Alex Riding, Mark Southwood, Joanna Pepke-Zaba, Andrew Exley, Richard C Trembath, Francesco Colucci, Mark Wills, John Trowsdale, Nicholas W Morrell.   

Abstract

BACKGROUND: Beyond their role as innate immune effectors, natural killer (NK) cells are emerging as important regulators of angiogenesis and vascular remodeling. Pulmonary arterial hypertension (PAH) is characterized by severe pulmonary vascular remodeling and has long been associated with immune dysfunction. Despite this association, a role for NK cells in disease pathology has not yet been described. METHODS AND
RESULTS: Analysis of whole blood lymphocytes and isolated NK cells from PAH patients revealed an expansion of the functionally defective CD56(-)/CD16(+) NK subset that was not observed in patients with chronic thromboembolic pulmonary hypertension. NK cells from PAH patients also displayed decreased levels of the activating receptor NKp46 and the killer immunoglobulin-like receptors 2DL1/S1 and 3DL1, reduced secretion of the cytokine macrophage inflammatory protein-1β, and a significant impairment in cytolytic function associated with decreased killer immunoglobulin-like receptor 3DL1 expression. Genotyping patients (n=222) and controls (n=191) for killer immunoglobulin-like receptor gene polymorphisms did not explain these observations. Rather, we show that NK cells from PAH patients exhibit increased responsiveness to transforming growth factor-β, which specifically downregulates disease-associated killer immunoglobulin-like receptors. NK cell number and cytotoxicity were similarly decreased in the monocrotaline rat and chronic hypoxia mouse models of PAH, accompanied by reduced production of interferon-γ in NK cells from hypoxic mice. NK cells from PAH patients also produced elevated quantities of matrix metalloproteinase 9, consistent with a capacity to influence vascular remodeling.
CONCLUSIONS: Our work is the first to identify an impairment of NK cells in PAH and suggests a novel and substantive role for innate immunity in the pathobiology of this disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22832786     DOI: 10.1161/CIRCULATIONAHA.112.110619

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

1.  Comparing pulmonary hypertension severity between rat strains suggests right ventricle NK cells are protective.

Authors:  Claudia Mickael; Michael H Lee; Sue Gu; Brian B Graham
Journal:  Cardiovasc Res       Date:  2019-03-15       Impact factor: 10.787

Review 2.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

3.  Pulmonary hypertension begets pulmonary hypertension: mutually reinforcing roles for haemodynamics, inflammation, and cancer-like phenotypes.

Authors:  Danchen Wu; Stephen L Archer
Journal:  Cardiovasc Res       Date:  2016-05-23       Impact factor: 10.787

Review 4.  Can intestinal microbiota and circulating microbial products contribute to pulmonary arterial hypertension?

Authors:  Thenappan Thenappan; Alexander Khoruts; Yingjie Chen; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-09-06       Impact factor: 4.733

5.  A novel pro-angiogenic function for interferon-γ-secreting natural killer cells.

Authors:  HyunSoo Lee; Simona L Schlereth; Eun Y Park; Parisa Emami-Naeini; Sunil K Chauhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-02       Impact factor: 4.799

Review 6.  Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra.

Authors:  Keshava Rajagopal; Andrew J Bryant; Sandeep Sahay; Nancy Wareing; Yang Zhou; Lavannya M Pandit; Harry Karmouty-Quintana
Journal:  Br J Pharmacol       Date:  2020-04-07       Impact factor: 8.739

7.  Emerging hemodynamic signatures of the right heart (Third International Right Heart Failure Summit, part 2).

Authors:  Bradley A Maron
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

9.  Discovery of Distinct Immune Phenotypes Using Machine Learning in Pulmonary Arterial Hypertension.

Authors:  Andrew J Sweatt; Haley K Hedlin; Vidhya Balasubramanian; Andrew Hsi; Lisa K Blum; William H Robinson; Francois Haddad; Peter M Hickey; Robin Condliffe; Allan Lawrie; Mark R Nicolls; Marlene Rabinovitch; Purvesh Khatri; Roham T Zamanian
Journal:  Circ Res       Date:  2019-03-15       Impact factor: 17.367

Review 10.  Relevant issues in the pathology and pathobiology of pulmonary hypertension.

Authors:  Rubin M Tuder; Stephen L Archer; Peter Dorfmüller; Serpil C Erzurum; Christophe Guignabert; Evangelos Michelakis; Marlene Rabinovitch; Ralph Schermuly; Kurt R Stenmark; Nicholas W Morrell
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.